In a report issued on February 23, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a price target of $35.00. The company’s shares closed last Friday at $9.43, close to its 52-week low of $8.33.
According to TipRanks.com, Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -27.4% and a 21.6% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Crispr Therapeutics AG, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Allogene Therapeutics is a Strong Buy with an average price target of $30.33, representing a 226.8% upside. In a report issued on February 25, JMP Securities also reiterated a Buy rating on the stock with a $23.00 price target.
The company has a one-year high of $39.12 and a one-year low of $8.33. Currently, Allogene Therapeutics has an average volume of 1.48M.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALLO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Read More on ALLO: